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Opiate dependence is a phenomenon which confronts all
(European) countries and it is a costly problem, both in public
spending and in human suffering. Opiate dependence is
considered a major contributor to poverty, crime, family dis-
integration and to government spending at the local and
national level. 
Substitution treatment has proved effective for the individual
and for civil society as it improves the social, mental and
physical well being of the individual and reduces public
spending in health care and the criminal justice system.
Substitution treatment delivered appropriately will:
- Reduce or stop illegal drug use
- Improve physical, mental and social well-being of the patient
- Prevent and reduce infectious diseases, including HIV and 
hepatitis
- Reduce mortality, in particular through overdose
- Reduce morbidity
- Improve the quality of life of the patient and his family
- Reduce public spending in health care 
- Reduce public spending in the criminal justice system
The benefits of substitution treatment are maximised by: 
- Retaining clients in treatment
- Prescribing adequate dosages of medication (in the case of 
methadone usually between 60-120 mg or higher and in the 
case of buprenorphine 8 mg or more)
Executive summary
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- Maintenance rather than abstinence 
- Offering counselling
- Assessment and treatment of psychiatric co-morbidity
- Availability of psycho-social interventions and encouraging 
integration between different services.
While the efficacy of opiate substitution treatment has been
well proven, there are significant challenges ahead:
Making treatment as cost-effective as possible while main-
taining or improving the quality of care
Increasing the availability and variety of treatment services
Providing additional funding for opiate addiction treatment
and coordinating these services with other necessary social
services and medical care.
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Executive summary
Opiate dependence exists all across Europe and causes
problems not only at the level of individual patients and their
families, but also for civil society. Opiate dependence is a
major contributor to poverty, crime, family disintegration and
to government spending at local and national level. 
Scientific evidence suggests that substitution treatment can
help reduce criminality, infectious diseases and drug-related
deaths as well as improve the physical, social and psycho-
logical well-being of the patients. 
Despite the expansion of substitution treatment in Europe in
recent years, there remain several challenges to be tackled,
which include:
- Lack of quality control: Monitoring or assessment of
individual programmes is needed in order to improve the
quality and cost-effectiveness of treatment 
- Limited availability: Most people with an opiate dependence
today are not in substitution treatment, either because it is
not available or because current treatment does not meet the
needs of the patient
- Political agenda: Although the evidence base exists in support
of substitution treatment ideological and political considera-
tions against it often prevail
- Lack of consensus: There is still confusion and disagreement
about the nature of addiction and about the value of
substitution treatment. 
Why this information on 
substitution treatment
for policy makers?
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This booklet summarises the facts about effective substitution
treatment for opiate addiction. The information provided is
given in the form of frequently asked questions, which people
working in the field are confronted with. We have sorted these
questions into four chapters and provide answers, based on
scientific evidence and current practice, which could help you
when discussing the importance of implementing substitution
treatment in your area.
Given the differences in historical, cultural, social, economic
and political background as well as differences in how health-
care is organised within Europe we have tried to remain as
general as possible. One has to keep in mind the diversity in
the current availability, stage and state of substitution
treatment in Europe, the differences between Western Europe
and Central – and Eastern Europe and even within individual
countries. Although at several stages certain aspects or
treatment options are recommended, we do not intend to
dictate, but rather provide guidance and suggestions for good
clinical practice of substitution treatment. In the end, every
community needs to reach its own consensus and this booklet
can be instrumental in this process. It can provide a know-
ledge base for implementing and sustaining drug treatment
programmes that will be effective both for the individual as
well as to civil society. 
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1a1a.What is drug dependence?
Drug dependence is a complex condition with social, psycho-
logical and biological components. Drug users do not form a
homogeneous group, because there are many forms of drug
dependence, varying in types of drugs used and the level of
dependence. 
There are many drugs which can cause dependence, including
legal ones such as alcohol, tobacco, prescribed drugs and coffee
and illegal ones such as opiates (most often heroin) and
stimulants (cocaine, speed, amphetamines, ecstasy). 
It is important to distinguish between drug use and drug
dependence. Tables 1 and 2 summarise the distinction between
people who can control their drug use and people with a drug
dependence or addiction. 
1. The health and social costs
of drug dependence
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1aTable 1: Drug usersDrug users who can consume drugs in a controlled way and perceive lowrisk, because of
Curiosity often the reason for initial drug use
Experimentation young people may experiment with 
drugs to fill in gaps in their 
knowledge 
Adventure, risk taking some people may be attracted by the risk they
see as inherent in drug use
Improve performance this may include the use of stimulants such 
& body image as cocaine and amphetamines, and perfor-
mance enhancers such as anabolic steroids
Enjoyment most people use drugs because they 
enjoy them
To enhance this will include the use of ecstasy by 
experience younger clubbers, and mescaline by 
older writers (e.g. Huxley) 
1. The health and social costs
of drug dependence
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1aTable 2: Problematic drug usersProblematic drug use, people who are dependent on the drug and whohave to use in order to
Avoid withdrawal Once dependent on drugs, users will wish to 
avoid the extremely unpleasant physical and 
psychological effects of withdrawing from 
their dependence 
To kill (emotional) pain Some people will use drugs (generally 
opiates) as a means of coping with emotional
pain as a form of self medication 
Apart from the differences between the drugs used and the
extent of the use, the way of administering drugs also
differentiates users. Some drugs can only be taken orally and
others can also be sniffed or injected. The most hazardous
pattern of drug use is found among dependent opiate injectors
who inject daily over many years. This group is faced with high
levels of mortality, including that caused by HIV/AIDS, hepatitis,
overdose, suicide and trauma (WHO, World Health Report,
2002)
1. The health and social costs
of drug dependence
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1b1b.What is opiate dependence?
Opiate dependence is a condition in which the neuro-chemistry
and receptor sites of the brain change, causing the need for
opiates to become as biologically driven as the need to eat or
breathe. 
1. The health and social costs
of drug dependence
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1c1c.How big is the problem of opiate dependence?
Because opiates are illegal drugs the use is often hidden, hence
it is difficult to estimate the number of people using or
dependent on them. 
In Europe all countries have been confronted with a drug
problem. The introduction of the opiate epidemic however
varied across the continent: 
- In the late 60’s and early 70’s among young people in North 
Western Europe
- In the late 70’s and early 80’s in Southern Europe
- In the 90’s in Central and Eastern Europe
Some of the Northern European countries such as Sweden and
Finland appear to have comparatively lower levels of heroin
dependence and higher rates of amphetamine use and
dependence (Farrell et al.,1999).
The European Monitoring Centre on Drug and Drug Addiction
(EMCDDA) provides general estimates of the number of
problematic opiate users per country in European Union Member
States. Portugal, Italy, Luxembourg and the UK score highest with
an estimate of between six to nine per 1000 inhabitants aged 16-
65. Estimates are lowest in Austria, Germany and the Nether-
lands, with about three problem drug users per 1000 inhabitants
aged 16-65 (EMCDDA Annual Report, 2002). 
1. The health and social costs
of drug dependence
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1cTable 3: Estimated prevalence in the European UnionEstimated number of problematic drug users per 1000 population aged16-65 in the EU in 2001:
Highest 6-9 Italy, Luxembourg, Portugal, the UK
3-6 Denmark, Finland, France, Ireland, Spain, 
Norway
Lowest 2-3 Austria, Germany, the Netherlands
1. The health and social costs
of drug dependence
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1d1d.What are the social and health consequences ofopiate dependence?
Dependence on illicit opiates is a serious condition which is
associated with severe morbidity, in particular HIV/ AIDS and
other infectious diseases (hepatitis B and C), and a high risk of
death. In many countries, injection is a major cause of HIV
infection amongst opiate users through the sharing of
contaminated injection material, with the risk of spreading it to
the general population through their sexual partners and
through maternal transmission. In addition, opiate addiction is
considered a major contributor to poverty, crime, family
disintegration and to government spending. Opiate depen-
dence can cause social, health and economic problems.
A British study by the University of York has calculated the
costs of the use of illegal drugs in the UK such as heroin, crack
and cocaine. These drugs are estimated to cost the nation
almost 30 billion Euro a year. Serious addicts account for 99
per cent of the total social and economic costs of drugs:
recreational users without a habit cost an average of €30 a
year, while problem drug users cost over €16,000 a year. The
annual economic costs to the health service and the criminal
justice and benefits systems are estimated at between €5.6
billion and €10.3 billion. The social costs of crime to victims
boost the figure to between €16.6 billion and €28.6 billion (The
Observer, press release 1.12.02).
1. The health and social costs
of drug dependence
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1dAn Australian study puts the cost of drugs to society intoperspective, comparing the social costs of smoking, alcohol andof illegal drugs. The calculations for the survey period, 1998-9,
included both tangible and intangible costs to individuals,
companies and governments. Tangible costs included hospital
care, road crashes, loss of productivity and tax revenue, and
increased crime and policing. The intangible costs included pain
and suffering. Smoking tobacco accounted for 61%, alcohol for
22% and illegal drugs for 17% of the social costs. 
1. The health and social costs
of drug dependence
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1e1e.Is there a cure for opiate dependence?
Opiate dependence is a chronic recurring condition and treat-
ment is a long process. There is a range of treatment options
available for opiate dependence, ranging from psycho-social
interventions in residential settings (including therapeutic
communities) or in outpatient settings (including self help such
as AA and NA) to medically assisted treatment including
substitution treatment or detoxification regimes in outpatient
settings, including specialised centres and primary care. The
different forms of treatment are not mutually exclusive but can
operate together for patients with different needs. 
Some of these options have proved more effective than others.
Substitution treatment given to an appropriate standard of care
has proved effective in producing many positive outcomes both
for the individual and for society in that they: 
- Reduce illegal drug use
- Improve physical, mental and social well-being of the patient
- Improve the quality of life of the patient and his family
- Reduce risk behaviour 
- Reduce public spending in health care 
- Reduce public spending in the criminal justice system.
Scientific evidence has shown that opiate addiction is best 
treated by a combination of continuing outpatient therapy,
medication and monitoring, with the goal of retaining patients
1. The health and social costs
of drug dependence
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1ein treatment to maximise and maintain the full benefits oftreatment (UNODC, 2003). Substitution treatment and inparticular methadone maintenance coupled with relevant social,
medical and psychological services has the highest probability of
being the most effective of all available treatments for opioid
addiction (Joseph et al, 2000; AATOD Drug Court Fact Sheet,
2002).
1. The health and social costs
of drug dependence
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2a2a. What is substitution treatment?
Opiate dependence is difficult to control due to compulsive drug
use and craving, leading to drug seeking and repetitive use,
even in the face of negative health and social conse-quences. At
this moment there is a wide range of treatment options
available and substitution treatment is for the majority of
opiate dependent people the most successful one. 
Substitution treatment is a form of medical care for opiate
dependence using a similar or identical substance with
properties and actions similar to the drug normally used. This
type of substance is called an agonist. Agonists can be
substituted for the drug of abuse to provide a more controll-able
form of addiction. Using them alleviates many of the
withdrawal symptoms often experienced by persons addicted to
various psychoactive substances and reduces the health and
social risks; when given in the right dosage it also reduces
craving for opiates. Methadone is an example of an opiate
agonist. 
Another medication prescribed for opiate dependence is 
buprenorphine. Buprenorphine is a synthetic partial agonist-
antagonist. An antagonist is a blocking agent which occupies 
the same receptor sites in the brain as the specific drug of abuse
but is non-addicting. When someone is taking an antagonist,
the effects of heroin are blocked because they cannot act on the
2. About substitution 
treatment
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2abrain in the usual way and there is no mood-altering effect. Pureantagonists, like Naltrexone, are used when people do not wantto be maintained on opiate substitutes or when leaving other
drug-free treatment programmes and re-entering the
community, to diminish the risk of relapse. Another opiate
antagonist, Naloxone (Narcan®) is used to treat opiate overdose
and to reverse coma.
The value of substitution treatment lies in the opportunity it
provides for dependent drug users to reduce their exposure to
risk behaviours and to stabilise their lives in health and social
terms. Substitution treatment is generally considered for
dependent users who find it difficult to stop their drug use and
complete withdrawal. It is desirable for substitution drugs to
have a longer duration of action, or half-life, than the drug they
are replacing so as to delay the emergence of withdrawal and
reduce the frequency of administration. This allows the person
to focus on normal life activities without the need to obtain and
administer drugs. Furthermore, the substitution of prescribed
medication for an illicit drug helps in reducing criminal activity,
supporting the process of lifestyle change.
2. About substitution 
treatment
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2b2b.What are the aims of substitution treatment?
The aims of substitution treatment can be summarised as to: 
- Assist the patient to remain healthy until, with the
appropriate care and support, they can achieve a life free of
illegal drugs
- Reduce the use of illicit or non-prescribed drugs by the 
individual 
- Deal with problems related to drug misuse 
- Reduce the dangers associated with drug misuse, particularly
the risk of death by overdose and of HIV, hepatitis B & C, and
other blood-borne infections from injecting and sharing
injecting paraphernalia
- Reduce the duration of episodes of drug misuse 
- Reduce the chances of future relapse to drug misuse
- Reduce the need for criminal activity to finance drug misuse
- Stabilise the patient where appropriate on a substitute 
medication to alleviate withdrawal symptoms
- Improve participation in other medical care
- Improve overall personal, social and family functioning.
These goals are achieved almost from day one of treatment for
many patients. Substitution treatment can be compared to other
drugs that are effective in treating serious chronic conditions
such as hypertension and diabetes. These conditions, like opiate
dependence, are chronic, require daily treatment, and have a
high risk of adverse effects if treatment is stopped.
2. About substitution 
treatment
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2c2c What is the extent of substitution treatment inEurope?
In Europe, substitution treatment has a long and varied history
across the continent where changes in medical opinion and
legislation have led to developments and changes in prescribing
practices. 
In the European Union action plan on drugs (2000-04), one of
the five strategy targets is defined as 'to increase substantially
the number of successfully treated addicts'. 
Most European countries today provide some form of
substitution treatment. The percentage of people with an opiate
dependence actually receiving treatment varies across countries
and within regions. In part this depends on the size and history
of the problem per country, and in part on the political will to
provide treatment on a large scale. 
For example, in Italy only between 27-29% receive substitution
treatment. In Spain, the percentage varies between 41 and 86%,
in Germany between 33 and 63% and in the Netherlands
between 40 and 47% of the heroin users receive substitution
treatment (EMCDDA, 2002).
Most countries have seen a rapid expansion in the provision of
substitution services, especially in Spain, France, and in some 
Central and Eastern European countries. The impetus for the 
2. About substitution 
treatment
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2cexpansion has largely been a response to the HIV/AIDSepidemic among drug users as well as the increased evidence
base of overwhelming effectiveness of substitution treatment
both for HIV prevention and for opiate dependence itself. Whilst
most countries have experienced few problems during this
growth period, concern has been expressed in some member
states. It concerns the lack of training and skills of some
practitioners who are now involved in substitute prescribing.
This is particularly noticeable among specialist services,
including general practitioners and pharmacists. There is also
concern about controls on prescribing and the risk of possible
diversion of methadone onto the illegal market (Farrell et
al.,1999).
2. About substitution 
treatment
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2d2d.What is methadone treatment?
Over 90% of opiate substitution in the EU is delivered in the form
of methadone, apart from France, where buprenorphine
prevails. It is estimated that approximately 300,000 people are
on methadone in Europe, 180,000 in the United States and 20,000
in Australia. There are many countries in the world where
different forms of drug substitution take place. However, the
bulk of methadone treatment to date is still carried out in
Europe, North America and Australia. These overall estimates
would suggest that around half a million people receive this type
of drug substitution globally (Farrell et al.,1999; Parrino, 1999).
Methadone is a synthetic opioid agonist with a half-life of between
24-36 hours. There are several forms and formulas of methadone.
The most widely used form is the liquid 1mg/1ml solution.  
The principal effects of methadone are relief of narcotic craving,
suppression of the abstinence syndrome, and blocking of the
euphoric effects associated with heroin. Because of the often
chronic nature of opiate dependence, the majority of patients
requires high doses and treatment for an indefinite period of
time. Methadone maintenance treatment, long term treatment,
has therefore proved more effective than shorter term treatment
or detoxification. Lower doses may not be as effective or provide
the blocking effect. Methadone maintenance has been found to
be medically safe and non-sedating. It is also a safe and effective
medication for pregnant women addicted to heroin.
2. About substitution 
treatment
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2e2e. Is methadone the only substitution medicationfor opiate dependence?
The vast majority of all substitution treatment is provided by
methadone, but there are some other medications available
and which are also effective in the treatment of opiate
dependence. Although only a minority of patients responds
poorly to methadone, other substitute medications need to be
available to them.
Buprenorphine
There is increasing evidence for the effectiveness of buprenor-
phine (Subutex® or Suboxone®) as a substitute medication.
Buprenorphine is a synthetic mixed agonist-antagonist medi-
cation and not a pure but a partial opioid agonist. Its
effectiveness seems comparable to methadone. Although it has
not proven to be more effective than methadone, some
individuals benefit from this partial agonist-antagonist. The
opioid effects of this medication are limited and thus
buprenorphine is less likely to produce overdose. Some
countries have made buprenorphine more available than
methadone, which in part may be based on overcoming
resistance to providing substitution treatment. In France for
example, the majority of substitution treatment is provided with
bupre-norphine. In 2000, there were only 5000 people receiving
methadone in France against an estimated group of 80.000
receiving buprenorphine. In Austria, 35% of patients receiving
2. About substitution 
treatment
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2esubstitution treatment receive buprenorphine; compared to 5%in Portugal and 15% in Germany. Buprenorphine has beenintroduced in office-based medicine in Australia in 2000, and in
the United States in October 2002. 
Some experts prefer buprenorphine for younger drug users and
methadone for older users on a long-term basis. Buprenorphine
also seems better for pregnant women, because it causes fewer
neonatal problems than methadone. On the other hand, metha-
done administration is easier to control, and in most countries it
is a lot cheaper than buprenorphine (EMCDDA, 2002).
Diamorphine
Several countries have initiated trials with prescribed heroin
(diacetylmorphine) as a form of substitution treatment for
severely addicted patients and for people who respond poorly to
methadone. Switzerland and the Netherlands have concluded
the trials and published the results. The main finding of both
studies was that for severely addicted, older, heroin users
methadone plus heroin was more effective than treatment with
methadone alone. Similar studies are currently being carried out
in Germany and are to be begun in the near future in the region
of Andalusia in Spain.
2. About substitution 
treatment
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2f2f.Why does substitution treatment need to be givenfor such a long time?
The chronic use of heroin causes changes in the chemistry of the
brain. The biology of the brain changes and may never revert
back to its pre-heroin state in a number of heroin-dependent
individuals. Opiate dependence is considered a chronic
relapsing condition and treatment should therefore be of a
chronic nature, just like for other chronic conditions such as
diabetes and hypertension.
Substitution treatment generally does not end physical
dependence but allows people to live a healthy life on a legal and
stabilising medication instead of an illegal and dangerous one
such as heroin. Although some people stop needing their
substitute medication, the majority will need to be maintained
on it for a long time. The important thing is that this stability is
the precondition for change and that coercive reductions of
medication without the agreement of the patient do not work.
Just as psychiatrists are not expected to withdraw depressed
patients from their antidepressant medication and as physicians
do not withdraw their patients from cardiovascular or other life
sustaining medications that stabilise the patient and enable
them to lead a normal life without struggling through the
debilitating effects of an illness, patients on opiate substitution
should not be required to withdraw from a medication that
improves their quality of life.
2. About substitution 
treatment
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Substitution treatment is effective both for the individual
patient and for society in general with regard to the general
public, public health and public spending. Scientific evidence
shows that substitution treatment reduces criminality,
infectious diseases and drug-related deaths and also improves
the physical, social and psychological well-being of the
patients. 
3. About the effectiveness
of substitution treatment 
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3a3a.What is the effectiveness for the individual?
Whilst most of the evidence on the effectiveness of sub-stitution
treatment comes from methadone, there is an increasing body
of evidence on the value of other medications, in particular on
buprenorphine. Substitution treatment has been shown to
improve the patient's physical well-being by helping patients
to:
- Stay alive
- Achieve abstinence from illicit drugs, or a reduced, stabilised 
pattern of drug use
- Move from impure, illicit drugs to pure pharmaceutically-
supplied drugs 
- Change the route of drug administration, from injecting to a 
less harmful way such as oral or sublingual administration
- Keep contact with services.
Furthermore, substitution treatment has proven to improve the
patient's social well-being by helping patients to:
- Stabilise their drug use as a means of stabilising their lives 
- Reduce the need to resort to criminal activity to source and 
fund their drug supply 
- Empower patients to make choices concerning their chosen 
lifestyles and life goals. 
Effectiveness or success of treatment depends not only on the 
substitution medication given, but also on the context and 
3. About the effectiveness
of substitution treatment 
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3aaccompanying aspects of treatment. Psychosocial interventionsfor example can have an important contribution to the successof substitution treatment. Substitution treatment allows people
to resolve other issues in life, such as housing, employment and
building a social network.
3. About the effectiveness
of substitution treatment 
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3b3b.What is the effectiveness for society?
The costs of drug use arise from:
- The loss of life through overdose and drug-related illness
- Treatment of overdose and other medical consequences of 
drug use
- The transmission of disease, particularly HIV and hepatitis, 
mainly through use by injection
- Loss of quality of life for the families of people with an 
opiate dependence
- Law enforcement and judicial costs
- Criminal activity
- Loss of productivity and workplace accidents
Although these costs are difficult to quantify and few data are
available where costs could be quantified, substitution
treatment, and in particular methadone treatment has been
proved to help to:
- Improve public health, especially reducing the level of drug-
related emergencies, hospital admissions, and mortality as 
well as halting the spread of HIV, hepatitis and other blood-
borne viruses 
- Reduce the level of criminality associated with the import, 
manufacture and supply of illicit drugs, and the level of 
acquisitive crime associated with the funding of drug habits 
- Reduce social welfare costs incurred by drug users and their 
dependents
3. About the effectiveness
of substitution treatment 
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3c3c.What are the cost-benefits of substitutiontreatment?
Of particular significance to policy makers in health-care and
criminal justice, is the fact that substitution treatment has also
shown to be extremely cost-effective. The US Department of
Substance Abuse Services (DASA) and the National Institute for
Drug Addiction in the USA have estimated the yearly cost of
maintaining an opiate addict in New York in 1991 (presented in
US dollars and Euros, respectively): 
Untreated on the street $43.000 - €40.000
In prison $43.000 - €40.000
In a residential drug-free 
programme $11.000 - €10.000
In methadone maintenance
treatment $ 2.400 - € 2.250
Source: International Forum, 1994. 
More recently, in 2001, DASA carried out another study in
collaboration with the University of Washington on the cost
effectiveness and efficacy of substitution treatment with the
following findings. 
Reduction of:
Property crimes 64%
Overall arrest rates 54%
3. About the effectiveness
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3cDrug offence arrests 63%Emergency room visits 65%
Medical hospital admissions 59%
Utilisation of major health care services 56%
Psychiatric hospitalisation 55%
Source: DASA, 2001
The rates of change are even higher for those who remain in
treatment for longer than a year. Arrest rates are especially likely
to be even lower among patients who remain in treatment over
the longer term.
More specifically with regard to substitution treatment in
Europe, the British National treatment Outcome Research Study
(NTORS) found that for every £1 (€1.5) spent on treatment
there is a return of more than £3 (€4.5) in terms of savings
associated with victim costs due to crime. The increased
expenditure of £1.6 million (€2.4 million) for treatment
interventions yielded an immediate cost saving of £4.2 million
(€6.3 million) in terms of the reduced victim costs of crime, as
well as cost savings within the criminal justice system of about
£1 million (€1.5 million). The true cost savings to society may
be even greater than this (Gossop et al., 1998). 
3. About the effectiveness
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3d3d.Is it a waste of public funds to invest insubstitution treatment? 
No, it is not. Investing in substitution treatment for opiate
dependence that is based on scientific evidence reduces the
negative health and social consequences both for the individual
and for civil society. Money spent on treatment is returned
manifold in cost-savings in the criminal justice system and
public health.
In the case of the individual patient and that of social policy the
aim of substitution treatment is to reduce harm. As drug
addiction is a condition not easy to overcome, it is important to
reduce the harm both to society at large and to the individual.
Good quality substitution treatment easily available for anybody
who needs it can save many other costs in health care, social
welfare and the criminal justice system.
For the planning and policy perspective it is important to
consider the problem of opiate dependence in a co-ordinated
way in order to assess the benefits not only for one field or
department, e.g. health, but also in another, e.g. the criminal
justice system.
3. About the effectiveness
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3e3e.Why are some people still critical of substitutiontreatment?
The stigma of drug dependency is still so strong in most places
that those who suffer from it must cope with life-long
embarrassment, blame, and rejection. In spite of all we know
about the biological nature of the condition, there is persistent
disapproval of those who have it, and denial of its prevalence
and impact. This powerful stigma keeps people from
acknowledging their condition and seeking treatment. It even
keeps some people from entering the profession of dependency
treatment and prevention, and often results in lower pay for
those who do (DASA, 2002). 
Apparently it is not enough to improve knowledge about the
effectiveness of substitution treatment. It is therefore important
to understand the psychosocial roots of this resistance. Kreek et
al. (1996) described two major reasons for this resistance. Our
society is dominated by values of work ethic, competition and
autonomy. Drug addiction seems to be dictated by values that
are dia-metrically opposed to these: the pursuit of pleasure,
passivity and dependence. Drug dependence is therefore
perceived more as a vice than as an illness or a problem, leading
to refusal to provide care. 
This perception is based on several misconceptions, however.
The first one is that heroin addicts experience continuing
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3epleasure while addicted. Heroin consumption brings pleasuremostly before the user becomes dependent on the drug.Subsequently, the accompanying problems far outweigh the
pleasure, but the user is compelled to continue using heroin in
order not to suffer from abstinence symptoms. 
The second misconception behind the refusal to provide
maintenance treatment is the belief that such treatment
prolongs the addicts pleasure, that all they do is ‘replace one
drug with another’. In reality, patients undergoing maintenance
treatment are in perfectly normal state of awareness with no
euphoria or ‘high’ and no withdrawal or ‘sick’ periods. 
Another misconception is that patients do not become drug-
free, hence no real change in the patient’s situation occurs.
People with such a view misunderstand the purpose of
substitution treatment. The value of opiate substitute treatment
is in the acute phase of opiate dependency – at the time when a
person is not able to stop using opiates. Substitution
medication can enable a dependent drug user to stop, or greatly
reduce, the use of illicit opiates. It can also assist in reducing or
eliminating injecting drug behaviour. 
The development of adequate treatment will require not only a
better dissemination of knowledge about the effectiveness of
substitution treatment, but also the demystification of the
prejudice existing in all sectors of society. 
In most countries each drug user has a right to receive
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3eprofessional treatment and care according to currently acceptedquality standards. Drug users are citizens with equalentitlements, having the same rights and duties as all citizens,
independent of whether they are undergoing professional
treatment as a result of their addiction.
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3f3f.Are there also disadvantages in substitutiontreatment?
Yes, there are also some negative aspects to substitution
treatment. The most important is the fact that in most cases a
person has to receive treatment for a long period of time. The
long term aspect has negative consequences both for public
spending and for the individual patient. 
Although substitution treatment is a cheap form of treatment,
when calculated over many years the price of treatment adds up. 
Another aspect is the fact that a person becomes a long term
patient dependent not only on the medication but also
dependent on the person who prescribes it. In some cases this
dependency can lead to a passive attitude. 
Furthermore, the dependency on the medication and the stigma
surrounding it will cause difficulties when a patient wants to
move from one place to another or simply travel and take along
his medication.
Some people experience side effects of the medication. In the
case of methadone the most common side effects include:
increased transpiration, constipation, and disturbances of sleep,
sex drive and concentration. Such undesirable side effects may
persist over longer periods of treatment, but mostly there are no 
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3fmedical consequences. In total, these side effects affect lessthan 20% of methadone clients.
Finally, although methadone is prescribed to pregnant women
as it improves her health status, the state of the pregnancy,
delivery and the development of the foetus, the newborn baby
will have to withdraw from the medication at birth. 
It is important to note, however, that the long-term need for
care, the dependence on the providers, passivity and resignation
are all serious problems that can arise, and should be
anticipated in caring for people with a severe chronic illness
(cardiac, renal, hepatic, oncological, etc). In conclusion, there
are some negative aspects of substitution treatment, which go
with chronic treatment in general, but they certainly do not
outweigh the benefits. 
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3g3g.What are the major challenges ahead?
While the efficacy of opiate substitution treatment has been
well proven, there are significant challenges ahead:
- Making treatment as cost-effective as possible while main-
taining or improving quality of care
- Increasing the availability and variety of treatment services
- Including and ensuring wide participation by (community 
based generalists) physicians trained in substance abuse to 
oversee medical care
- Providing additional funding for opiate addiction treatment 
and co-ordinating these services with other necessary social 
services and medical care organisations.
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Substitution treatment is delivered in a variety of ways, both in
different settings (primary care, specialised centres, pharma-
cies and in prison) and with varying dosages and duration of
treatment, including maintenance and detoxifi-cation regimes.
Furthermore, prescribing is often accompanied with a variety of
psychosocial interventions.
4. The delivery of 
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4a4a.Is substitution treatment alone enough?
Opiate dependence often has not only adverse effects on the
health of patients but also on their social and mental well-
being. It is important that substitution treatment is combined
with other components which assess and address these other
issues. The advantage of substitution treatment is that when
patients are maintained on methadone, other problems can be
addressed.
Scientific evidence has shown that the effectiveness of
substitution treatment is higher when it is provided as a
comprehensive treatment. Prescribing medication should there-
fore not be seen as an isolated intervention. It is important to
identify and address other problems such as medical, social,
mental health or legal problems. 
This does not necessarily mean that patients should be able to
address all their problems in one setting. When treatment is
provided by general practitioners or small centres with limited
staff, the assessment of the concurring problems could be
carried out by them and patients can be referred for additional
support to the appropriate services in the region. 
Many patients are in treatment for many years and will not
require additional care every time they come to receive their
medication. Although the staff may find this difficult to accept, 
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4aone has to consider that patients with another chronic relapsingconditions, such as hypertension or diabetes, will not be offered
counselling or psychotherapy every time they come for a new
prescription.
4. The delivery of 
substitution treatment 
on the effectiveness of substitution treatment for opiate dependence 43
4b4b.What is the best setting for substitution treatment?
There is considerable variation across Europe as to who can
prescribe substitution treatment for opiate dependence. In
countries such as Denmark, Finland, Greece, Italy, Portugal,
Spain and Sweden substitution treatment is provided centrally
in specialised programmes with little involvement of primary
care and General Practitioners (GPs). In Austria, Belgium,
France, Germany, Luxembourg, the Netherlands and the UK, on
the other hand, substitution treatment is less centralised and
both GPs and specialised centres prescribe. The situation will
depend on whether addiction treatment is considered a
specialised treatment or a primary care task (Farrell et al, 1999).
Specialised centres can provide both medical and psychosocial
care. Most specialised centres have a multidisciplinary staff,
including medical doctors, nurses, psychologists, drug workers,
and counsellors. The staff is specialised in opiate dependence
and has had specific training and/or background in the subject. 
In most countries, GPs who treat people with an opiate
dependence have had special training. GPs do not generally
have a multidisciplinary staff as they work on their own or in
conjunction with other GPs. However, GPs can liase with other
specialists in the field to whom they can refer patients for
psychosocial problems. For the dispensing, GPs need to work
closely with pharmacists. Providing substitution treatment in 
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4bprimary care normalises opiate dependence to the level of anyother treatable condition and patients are not separated from
others. 
Most prescribers of substitution medication want to see their
patients daily in the first phase of treatment, in particular during
the phase of induction when the proper treatment is stabilised.
Some doctors even prefer their patients to be supervised during
the first days or weeks of dispensing. Once patients are stabilised
it can be argued whether they need to come in daily to pick up
their medication or if they can be given take-home doses or
prescriptions. In many places, prescribers of opiate substitution
treatment work closely with the community pharmacies, where
their patients pick up the medication. Pharmacists have an
important role in providing relevant information to their clients.
They also have the responsibility to screen prescriptions for
potential mistakes or interaction with other medications.
Experience shows that it is important that both settings are
necessary for delivering treatment effectively. They allow patients
to move between programmes with different thresholds and cater
for geographical difficulties. Furthermore, what may work well in
an urban setting may not work in smaller towns or rural areas.
When budgets are extremely limited, prescribing medication
without any additional form of treatment or care can still be an
effective way of reaching as many people as possible and
offering them an important tool for recovery.
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4c4c.Should substitution treatment be also available inprison?
Yes, it is important that inmates have the same access to health
care as in the community. Research has shown that the
reduction of injecting and syringe sharing that occurs with
methadone maintenance treatment in community settings also
occurs in prison (Dolan et al, 1996). 
In 1998, the Prison and Drugs Conference in Oldenburg
presented recommendations for drug services in a prison
setting. They recommended that a wide range of drug services
should be available to prisoners, including substitution
treatment (both detoxification and maintenance). It was also
recommended that prison staff need to receive training in drugs
and related (health) problems. 
A recent article in the French professional media assessed the
likelihood of re-incarceration of drug-using inmates in
association with receipt (or non-receipt) of maintenance agonist
treatment while in gaol. The importance of substitution
treatment in prison on essentially the same terms as in the
community was stressed. In addition, it was found that inmates
who received maintenance treatment while incarcerated had
less than half (19% vs.39%) the likelihood of re-incarceration
than those who were detoxified only (Levasseur et al. Ann. Med.
Interne 2002. 153 Supple. to no. 3, pp 1514-1519).
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4cIndividuals on maintenance in the community should have theoption to continue to be maintained upon entry to prison. This
option is important since the discontinuity of methadone
maintenance treatment is likely to result in higher levels of risk
behaviour (Swiss Methadone Report, 1996).
People receiving substitution treatment in prison must be able
to continue with such treatment on release. There is a
particularly high risk of overdose and death after release if
patients have been abstinent from opiates. Decisions on
continuity should be taken in consultation with the treatment
programme in which the prisoner participates once outside
prison (European Recommendations, 1998).
There are some countries that provide methadone in all prisons
nationwide, such as Spain.
4. The delivery of 
substitution treatment 
on the effectiveness of substitution treatment for opiate dependence 47
4d4d.Is there a best way to provide treatment?
Yes, research evidence shows that substitution treatment is most
effective when delivered in an adequate dosage and for a long
period.
Substitution treatment is prescribed in many ways: ranging from
short- to long-term programmes and from maintenance to
detoxi-fication treatment.
Substitution treatment based on detoxification has the objective
to bring a person from a high dosage to a low dosage or to
nothing within a certain time frame, in general over a short
period. Maintenance treatment on the other hand acknowledges
the chronic nature of the condition and has the objective to
bring about stability in the life of the person, allowing for a stable
dose over a long period of time. The ultimate goal of
maintenance treatment can still be to eventually bring about
detoxification but only when the patient is ready for this. 
The treatment plan will depend on the objectives of the
treatment, which are established on the basis of the possibilities
available, the needs and wishes of the patient and the
professional opinion of the doctor. In general terms, however, it
can be stated that the severer the dependence, the higher the
dosage , and the focus should be more towards maintenance
than to detoxification. 
4. The delivery of 
substitution treatment 
48 information for policymakers
4e4e.Is there an optimal dosage?
Substitution treatment prescribes medication and, like all
medications, proper dosing is determined through the doctor-
patient relationship, taking into account the patient’s medical
assessment of individual (metabolic) needs and other medical
conditions and treatments. 
Substitution treatment has been widely evaluated and has
generally proved effective in achieving goals such as reducing
the consumption of illegal drugs, risk behaviour and crime. For
both methadone and buprenorphine, sufficient dosages have
shown to be imperative to ensuring positive outcomes
(EMCDDA, 2002).
The optimal dose of methadone for an average opiate-
dependent person is between 60-120 mg (and of buprenorphine
between 8-12 mg). 
Dosages below 60 mg are generally not effective as they are not
high enough to provide the blocking effect on the brain cells.
Attitudes or opinions about methadone dosing that are not
based on scientific evidence on effective dosing undermines the
potential value of the treatment. 
In conclusion, evidence suggests that the severer the
dependence, the higher the dosage should be and the longer the
treatment should last (Farrell et al, 1999).
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4eHowever, each patient presents a unique clinical challenge, andthere is no way of prescribing a single best methadone dose toachieve a specific blood level as a ‘gold standard’ for all patients.
Clinical signs and patient-reported symptoms of abstinence
syndrome, and continuing illicit opioid use, are effective
indicators of dose inadequacy. There does not appear to be a
maximum daily dose limit when determining what is ‘enough’
methadone in methadone maintenance treatment (MMT)
(Leavitt et al., 2000).
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4f4f.Is urinalysis a useful therapeutic tool?
Urinalysis is a vital part of the initial medical assessment of the
patient (for confirmation that the patient is actually using
opiates). 
However, it is often used as a form of control over patients to
see if they are not continuing to use illegal drugs with their
medication. Many professionals question its effectiveness as a
contributing factor to the success of treatment. It is argued that
the information can also be obtained by asking the patient,
which would save a lot of time and money. It goes without saying
that this requires a good patient-doctor relationship, which is
based on respect and mutual trust. However, it is also argued
that a positive urine test should never be the reason for
discontinuing treatment as it is evidence of symptoms of the
condition the patient is being treated for, i.e. drug dependency.
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4g4g.How to optimise the quality of substitutiontreatment?
In order to improve the quality of substitution treatment in your
area training is an essential tool. You can involve local trainers
and they can use the Euromethwork training manual we have
developed: 
AD Verster and E Buning (2003). Training manual: Key aspects
of substitution treatment for opiate dependence.
In you have no access to local trainers you can contact us for
advice on international experts: www.euromethwork.org.
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Abstinence: refraining from the use of alcohol or other drugs. 
Addiction: a chronic, progressive, relapsing disorder characterised by
compulsive use of one or more substances that results in physical,
psychological, or social harm to the individual and continued use of the
substance or substances despite this harm. 
Agonist: pharmacological term for the use of a drug that has a similar
action to the drug of dependence. 
Antagonist: pharmacological term for the use of a drug that blocks the
action of another drug.
Craving: physical and psychological need to use the drug of dependence.
Dependence: a psychological and/or physical need for the drug. When
the drug is not used the person experiences withdrawal symptoms. 
Detoxification: a form of treatment with the objective to bring a person
from a high dosage to a low dosage or to nothing within a certain time
frame, in general in a short period.
Drug of abuse: any substance that alters the mood, level of perception,
or brain function. These substances include prescribed medications,
alcohol, solvents, and illegal drugs. 
Half life: amount of time it takes before half of the active elements are
either eliminated or broken down by the body. Methadone has a half life
of 24 to 36 hours allowing for one daily dose as compared with heroin
that has a half life of around 6 hours.
Lexicon of terms
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Maintenance: a form of treatment that acknowledges the chronic nature
of the condition with the objective to bring about stability in the life of
the person, allowing for a stable dose over a long period of time.
Psycho-active substance: a chemical with an effect on the central
nervous system that alters mood and/or behaviour. 
Relapse: the return to substance use after a period of abstinence. 
Substitution treatment: medical treatment of opiate addiction with a
drug that has a similar action to the drug of dependence (agonist in
pharma-cological terms), thereby preventing withdrawal syndromes and
craving. 
Tolerance: the need for increasing doses of a substance to maintain its
effects. 
Withdrawal: physical and psychological effects that occur when opiate
consumption is significantly decreased or stopped. There is a craving for
the drug when one is abstinent, and these symptoms are relieved when
the drug is again taken or when a substitution medication such as
methadone is taken.
Lexicon of terms
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